Mitchell Finer
Director/Board Member bij TURMERIC ACQUISITION CORP.
Vermogen: 60 555 $ op 31-12-2023
Oorsprong van het eerstegraads netwerk van Mitchell Finer
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
University of California, Berkeley
344
| College/University | Other Consumer Services | 344 |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.
280
| College/University | Other Consumer Services | 280 |
| Public Company | Pharmaceuticals: Major | 41 | |
| Public Company | Biotechnology | 32 | |
| Public Company | Biotechnology | 26 | |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ.
24
| Subsidiary | Pharmaceuticals: Major | 24 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.
21
| Extinct | Pharmaceuticals: Major | 21 |
| Subsidiary | Pharmaceuticals: Major | 15 | |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA.
13
| Subsidiary | Biotechnology | 13 |
CODA Biotherapeutics, Inc.
 CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA.
10
| Holding Company | Medical Specialties | 10 |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer.
10
| Holding Company | Biotechnology | 10 |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.
8
| Holding Company | Biotechnology | 8 |
| Private Company | Financial Conglomerates | 7 | |
LifeEDIT Therapeutics, Inc.
 LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing private company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021.
3
| Subsidiary | Miscellaneous Commercial Services | 3 |
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Intracel Corp.
1
| Extinct | Pharmaceuticals: Other | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Mitchell Finer via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Operating Officer | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder Corporate Officer/Principal Chief Operating Officer Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Director/Board Member Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Chief Executive Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Executive Officer Corporate Officer/Principal Director of Finance/CFO | |
| OREXIGEN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| CHIASMA, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Corporate Officer/Principal Private Equity Investor Founder Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Stanford University | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree | |
| PACIRA BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Corporate Officer/Principal Undergraduate Degree Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| Yale University | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Director/Board Member Masters Business Admin Graduate Degree | |
| Princeton University | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| The University of California, San Francisco | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Director/Board Member | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| Kellogg School of Management | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Verana Health, Inc.
 Verana Health, Inc. Packaged SoftwareTechnology Services Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA. | Packaged Software | Founder Director/Board Member Director/Board Member | |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Founder Chairman Director/Board Member | |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Biotechnology | Founder Chief Executive Officer Director/Board Member | |
| HARPOON THERAPEUTICS, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| ALLOVIR, INC. | Biotechnology | President Director/Board Member Director/Board Member Chairman | |
| ARAVIVE, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member | |
| CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Consultant / Advisor Corporate Officer/Principal Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 46 |
| Verenigd Koninkrijk | 4 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 31 |
| Consumer Services | 12 |
| Commercial Services | 5 |
| Finance | 5 |
| Technology Services | 2 |
Operationeel
| Director/Board Member | 758 |
| Corporate Officer/Principal | 281 |
| Independent Dir/Board Member | 194 |
| Chairman | 129 |
| Chief Executive Officer | 115 |
Sterkste connecties
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| Luke Evnin | 42 |
| Stephen Knight | 39 |
| Thomas Woiwode | 39 |
| Todd Foley | 38 |
| Mark Blumenkranz | 35 |
| Alan J. Lewis | 33 |
| Daniel Lynch | 32 |
| Paul Wachter | 31 |
| Shelley Chu | 31 |
| Clarence Machado | 29 |
| Auerbach Daniel | 27 |
| Raju S. Kucherlapati | 27 |
| David M. Stack | 27 |
| Edward Hurwitz | 27 |
- Beurs
- Insiders
- Mitchell Finer
- Bedrijfsconnecties
